In addition to monotherapy with small molecule kinase inhibitors, there is biological rationale to evaluate treatments of kinase inhibitors in combination with mAbs that target the extracellular domain of EGFR in EGFR exon 20 insertion mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.